Navigation Links
Luminex Corporation Reports First Quarter 2012 Results
Date:4/30/2012

ercentages) Three Months EndedMarch 31,Variance20122011($)(%)(unaudited)System sales

$
,998$
7,679$
(681)-9%Consumable sales

11,90015,002(3,102)-21%Royalty revenue

8,2427,25698614%Assay revenue

17,2979,5847,71380%All other revenue

4,2903,75453614%$
48,727$
43,275$
5,45213%"Luminex delivered a solid financial and operating performance for the first quarter of 2012," said Patrick J. Balthrop, president and chief executive officer of Luminex.  "Our assay category showed excellent growth, driven by continued execution in our core assay franchises such as our xTAG® Cystic Fibrosis product line, growing demand outside the U.S. for our innovative xTAG Gastrointestinal Pathogen Panel (GPP), and a strong contribution from Luminex Madison. As expected, consumable revenue in the first quarter faced a difficult year-over-year comparison, yet grew 18% sequentially. In addition, we continue to grow our installed base at a healthy rate and are pleased to have expanded our distribution partners for our MAGPIX system with the addition of Bio-Rad Laboratories announced in early April." 

"Regarding new product initiatives, I am pleased to report that Luminex has received CE Marking for its NeoPlex4 assay and fully automated NeoPlex system. This product offering addresses a sizeable new market opportunity for Luminex and we are excited about the clear advantages offered to the public health lab customer," added Balthrop. "NeoPlex4 is another example of how Luminex provides advanced solutions and real value to our customers. With new assays like GPP, NeoPlex4 and the exciting portfolio from Luminex Madison, we are positioned for continued strong growth in the future," Balthrop concluded. 

"While we are pleased that both reportable segments achieved GAAP profitability in the first quarter of 2012, we experienced a decline in total operating income year-over-year primarily as a result of
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012
2. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
3. Luminex Corporation Vice President of Biodefense to Speak at DTRAS 2011 CBD S&T Conference
4. Luminex Corporation Reports Third Quarter 2011 Results
5. Luminex Corporation Receives Deloitte Technology Fast 500™ Award
6. Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011
7. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
8. Luminex Corporation to Present at Upcoming Investment Conferences In September
9. Luminex Corporation Reports Second Quarter 2011 Results
10. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
11. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 The new 13-valent ... as the previous version used prior to 2010, the ... Permanente study published today in Vaccine. The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
(Date:5/22/2013)... YORK , May 22, 2013 ... LLP is investigating claims on behalf of investors of ... ISRG ) (CUSIP: 46120E602) who purchased Intuitive ... 18, 2013 (the "Class Period"). Such investors are advised ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ...
(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... , , ... OPTR ) today announced that new data highlighting ... vancomycin-resistant enterococci (VRE) acquisition from Optimer,s North American phase 3 ... Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. , ...
... HONG KONG, Sept. 15 Data from multiple clinical trials ... stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent ... symposium, TCT 2009, in San Francisco. , , ... Center in Amsterdam will provide the final 12-month outcomes from ...
Cached Medicine Technology:Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 6Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009 3
(Date:5/23/2013)... May 23, 2013 Footwear etc. is pleased ... Vista Collection of sandals containing cork footbeds. Known for its ... consistently good sales for many years, and with this new ... summer. , Dansko Shoes and Sandals are ... Collection is no exception. Containing leather and patent leather uppers ...
(Date:5/23/2013)... May 23, 2013 Following the recent ... UK internet users, the security team at idcloak Technologies ... safeguards against this or any web-born malware. Gill-Chris ... technology provides far better privacy and security ... underlined that even the best AV software cannot be ...
(Date:5/23/2013)... 2013 Long-Term Care Insurance shopping ... rate at which applicants for Long Term Care Insurance are ... , The decision to buy a Long Term Care ... willing and able to purchase protection are increasingly being turned ... any price. A variety of chronic conditions appear to ...
(Date:5/23/2013)... 2013 When Teachers Notebook reached out ... raise funds for the Moore, OK tornado victims, they ... items that could be sold for around $10.00 with ... at Teachers Notebook were overwhelmed by the response from ... of materials within the first 12 hours of the ...
(Date:5/23/2013)... 2013 AttorneyOne.com, a recognized authority on ... actively providing expert opinion in view of the recent ... According to court documents, on March 5, 2013 a ... (case no. 3:2013cv50102) alleging that her husband suffered massive ... Pharmaceuticals, is mainly used as a blood thinner for ...
Breaking Medicine News(10 mins):Health News:Footwear etc. Announces the New Collection of Dansko Cork Sandals 2Health News:Effective virus protection without anti-virus software, identifies idcloak 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 3Health News:Teachers Rally to Raise Funds for Moore Tornado Victims 2Health News:New Lawsuit on Pradaxa Brain Hemorrhage: Now, AttorneyOne Can Provide Advice 2
... ... chairman of the board of directors for PerfectServe, a clinical communications company currently serving ... ... Gene Barduson was recently named executive chairman of the board of directors for ...
... , , BOCA RATON, ... the market leader in all-natural herbal and homeopathic remedies for ... as their PR firm of record. The company,s two brands, ... provide complete lines of safe, scientifically-tested, guaranteed products that promote ...
... AllegroMedical.com partners with ... ... help find a cure for spinal cord injury: The online retailer of medical supplies ... is a forward-thinking manufacturer of catheters. In an effort to facilitate finding a cure ...
... more emotional and behavioral difficulties when compared to other ... most when a parent is deployed overseas, according to ... having a parent deployed for a longer period of ... with emotional problems were important factors associated with whether ...
... , , Consumers ... SILVER SPRING, Md., Dec. 6 The U.S. Food and Drug ... San Antonio Bay on or after Nov. 16 due to reports ... from this area, which is located on the Gulf of Texas. ...
... College of Wisconsin, in Milwaukee, found a substantial variation ... disease complications in children. Barriers to its use on ... identified. The study led by Amanda M. Brandow, ... College and Children,s Research Institute at the Children,s Hospital ...
Cached Medicine News:Health News:Gene Barduson Named Chairman of PerfectServe Board of Directors 2Health News:Native Remedies and PetAlive.com Hires TransMedia Group to Herald Herbal for People and Pets 2Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: